Oct 05, 2022
Version 1
Protocol V.1
- Tea Borkowska1,
- Nikoloz Chkhartishvili1,
- Ekaterine Karkashadze1,
- Otar Chokoshvili1,
- Pati gabunia1,
- Lali Sharvadze1,
- Tengiz Tsertsvadze1
- 1Infectious Diseases, Infectious Diseases, AIDS & Clinical Immunology Research Center, Tbilisi, Georgia
Protocol Citation: Tea Borkowska, Nikoloz Chkhartishvili, Ekaterine Karkashadze, Otar Chokoshvili, Pati gabunia, Lali Sharvadze, Tengiz Tsertsvadze 2022. Protocol. protocols.io https://dx.doi.org/10.17504/protocols.io.3byl4jke8lo5/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working.
Created: October 05, 2022
Last Modified: October 05, 2022
Protocol Integer ID: 70865
Keywords: HIV, diabetes, hyperglycemia, mortality, Eastern Europe, Georgia
Disclaimer
DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK
The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to protocols.io is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with protocols.io, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.
Abstract
Abstract
Background
Life expectancy and quality of life of people living with HIV have been dramatically improved after introducing antiretroviral therapy, and the prevalence of non-communicable diseases has increased. Several studies have found that hyperglycemia with or without type 2 diabetes was associated with poor outcomes in people living with HIV.
The study’s objective was to determine the prevalence of hyperglycemia and assess its impact on mortality.
Materials and Methods
A retrospective cohort study was conducted among people living with HIV diagnosed in 2012-2018 and followed through 2020 at the Infectious Diseases, AIDS and ClinicalImmunology Research Center in Tbilisi, Georgia. Primary outcomes of interest included the prevalence of hyperglycemia and mortality. Causes of death were classified according to the Coding of Death in HIV(CoDe) protocol.
Results
Our study included 2914 people living with HIV. Two hundred and forty-two (8.3%)patients had hyperglycemia, with an increasing prevalence by age. Three hundred one(9.7%) participants died over the median 3.71 (IQR: 2.14-5.37) years of follow-up. Among these, 139 (46.2%) were due to AIDS-related causes, 123 (40.9%) – were due to non-AIDS causes, and in 39 (12.9%) cases, the cause of death could not be determined. Overall, the cohort contributed to 11,148 person-years offollow-up (PYFU), translating into a mortality rate of 2.70 deaths per 100 PYFU. The mortalityrate was significantly higher among individuals with hyperglycemia - 11.17 deaths per 100PYFU vs 2.07 deaths per100 PYFU amongnormoglycemicpatients(p<0.0001).
Conclusions
Hyperglycemia was associated with increased odds of mortality. Screening andmanagement of hyperglycemia should be integrated into routine HIV clinical services as part of acomprehensivecarepackage.
Materials
Hyperglycemia_dataset.xlsx Prepare database just like one in the Materials section.
Analyse the data contained in database.
Formulate conclusions.